FIELD: medicine.
SUBSTANCE: invention relates to psychiatry and can be used in treating depression. Method according to the invention involves intranasal administration during the first induction phase of at least 4 weeks from 28 mg to 84 mg of esketamine to a patient who has not responded to at least two oral antidepressants in the current depressive episode. Patient is assessed during the first induction phase if the patient cannot achieve an almost complete response to esketamine, repeatedly administering to patient from 28 mg to 84 mg of esketamine simultaneously with the second oral antidepressant in the second induction phase of at least 4 weeks. First oral antidepressant and the second oral antidepressant are independently sertraline, escitalopram, venlafaxine, duloxetine, or fluoxetine.
EFFECT: using the invention enables treating therapeutically resistant depression.
15 cl, 172 tbl, 82 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATMENT OF BIPOLAR DISORDER | 2011 |
|
RU2653408C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| 9-AMINOMETHYLMINOCYCLINE COMPOUNDS AND THEIR APPLICATION | 2017 |
|
RU2760186C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DGLA, AND USE THEREOF | 2015 |
|
RU2714323C2 |
| METHODS FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS | 2017 |
|
RU2766577C2 |
| METHODS OF TREATING DISEASES ASSOCIATED WITH S1P1 RECEPTOR | 2021 |
|
RU2821032C1 |
| TREATMENT OF MYOCARDIAL INFARCTION WITH REGENERATED HIGH-DENSITY LIPOPROTEIN | 2017 |
|
RU2798830C2 |
| TREATING POSTTRAUMATIC STRESS DISORDER | 2008 |
|
RU2458691C2 |
| COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR EVENTS | 2014 |
|
RU2711638C2 |
